Navigation Links
Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test
Date:1/15/2014

ted data.

“This collaboration will directly benefit breast cancer patients, survivors and their physicians by providing them with two powerful integrated tools,” said André de Fusco, Cynvenio’s CEO. “The ClearID Breast Cancer test offers genomic insights from a standard blood draw analyzed by next gen sequencing. By pairing ClearID with the CollabRx Therapy Finder we can now take into account an individual patient’s molecular (tumor) data when offering the latest insights into breast cancer treatments. This is a milestone in our efforts to provide individualized breast cancer screening and surveillance.”

“The CollabRx Therapy Finder for breast cancer provides patients with an up-to-date and easily accessible tool to navigate therapy considerations that incorporate molecular data and also receive curated news that pertains to their disease,” said Thomas Mika, Chairman, President & CEO of CollabRx. “We are excited to collaborate with Cynvenio on its introduction with the goal of providing metastatic breast cancer patients with an easy to use tool to aid in treatment planning by contexualizing the state of scientific and medical research backed by sound science.”

The companion announcement from CollabRx is available on: http://www.collabrx.com.

About Cynvenio Biosystems, Inc.

Cynvenio is a cancer diagnostics company focused on transforming cancer treatment and management through the molecular analysis of tumor biomarkers in the bloodstream. This expertise has resulted in two distinct product offerings: ClearID Breast Cancer monitoring program and LiquidBiopsy. ClearID Breast Cancer, designed for use by patients and their physicians, is a cancer detection and monitoring program that assesses 50 oncogenes for more than 4,500 genetic mutations using next-generation sequencing. This test and real-time molecular analysis provide a
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cynvenio Biosystems to Present Clinical Data on Mutational Analysis of LiquidBiopsy® Tumor Samples at the 2013 ASCO Annual Meeting
2. Cynvenio Biosystems Receives CLIA Certification for its Genomic Sequencing Laboratory
3. Cynvenio and CollabRx Announce Partnership for Cancer Molecular Diagnostics
4. Fortis Offers Bachelor of Science in Nursing Degree Program to Florida Students
5. Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery
6. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
7. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
8. Big Saver: Molderizer Offers 30% Mold Remediation Products Price Cut
9. Tri-Valley Sedation Dentist Dr. Endre Selmeczy Now Offers High-quality Dental Restorations
10. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
11. Salimetrics Offers New Saliva Collection Aid for Easy Collection of Passive Drool Samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... April 28, 2015 The Pistoia Alliance, ... work together to lower barriers to innovation in R&D, ... project. , The Ontologies Mapping project has been ... practices for ontology management in life sciences R&D. The ... of standardized guidelines, tools and services to enable the ...
(Date:4/28/2015)... According to a 2013 report from ... medical treatment from burn injuries per year. Despite several ... formation of scars with subsequent contractures remains a major ... there is no adequate treatment. Contractures are a permanent ... can cause permanent deformity. , Synedgen has developed ...
(Date:4/28/2015)... 28, 2015 Reproductive endocrinologist Dr. Kaylen ... 7 couples battling infertility in this country, testified on behalf ... as the first state in the nation to consider creating ... to couples who desire to receive them. , Infertility affects ... that infertility is one of the few medical diseases that ...
(Date:4/27/2015)... HEIDELBERG , Alemania, April 27, 2015 ... patente para un nuevo receptor utilizando tecnología de descubrimiento ... no cubierta en el tratamiento de millones de pacientes ... anunciado hoy que ha recibido una patente en Europa ... el descubrimiento de Molecular Health de que EPHB4 es ...
Breaking Biology Technology:Pistoia Alliance Announces Start of Ontologies Mapping Project 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 3Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 2Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 3Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3
... 6 , 3Q09 Corporate Highlights: ... to Astellas Pharma Europe Ltd. Made significant progress ... VP Sales; Senior Director, Marketing; and Director, Commercial Operations ... Committee chairman , Upcoming 2009 Milestones: ...
... Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced ... REOLYSIN(R) in patients with sarcomas metastatic to the lung ... Tissue Oncology Society Meeting held in Miami Beach, Florida, ... "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) ...
... ... place on February 22-24, 2010 in Philadelphia, has been announced. At this three day ... to share their experiences. , ... Minneapolis, MN (PRWEB) November 6, 2009 -- The agenda for Arrowhead’s ...
Cached Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
(Date:4/13/2015)... -- higi, a leading cloud-based consumer engagement platform that provides ... their communities around health and wellness, announced today the ... ... convenient vehicle to receive validated health information from consumers. ... API will allow higi,s trusted partners, on a user ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... decades, crop breeders have increasingly relied on the wild and ... resistance, drought tolerance, and other traits. But just like all ... at risk of decline and extinction due to habitat loss, ... two speakers will describe the latest efforts to identify and ...
... Ohio The discovery of genetic differences affecting up ... guesswork out of prescribing the correct dose of 25 ... The scientists found two genetic variants that alter ... or metabolizing, drugs ranging from the painkiller codeine to ...
... 10 per cent of the UK is left handed ... world. But why exactly someone is left or right handed ... Nottingham,s Professor John Armour and Dr Angus Davison, in collaboration ... genetic determinant, in influencing handedness. The researchers conducted ...
Cached Biology News:Protecting the weedy and wild kin of globally important crops 2New genetic discovery could reduce the guesswork in drug dosing 2New genetic discovery could reduce the guesswork in drug dosing 3New genetic discovery could reduce the guesswork in drug dosing 4What makes us left or right handed? New study rules out strong genetic factors 2